Comparison of clinical and parasitological data from controlled human malaria infection trials

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Roestenberg, Meta ^a   O'Hara, Geraldine A ^b   Duncan, Christopher J A ^b   Epstein, Judith E ^c   Edwards, Nick J ^b   Scholzen, Anja ^a   van der Ven, André J A M ^a   Hermsen, Cornelus C ^a   Hill, Adrian V S ^b   Sauerwein, Robert W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; CHLOROQUINE; MALARIA VACCINE;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; BLEEDING; BLOOD PARASITE; CHILL; CONTROLLED CLINICAL TRIAL (TOPIC); COUGHING; DIARRHEA; DIZZINESS; DROWSINESS; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; EPISTAXIS; FATIGUE; FLATULENCE; GINGIVITIS; HEART PALPITATION; HEMOGLOBINURIA; HUMAN; HYPERESTHESIA; INSOMNIA; LEUKOCYTE COUNT; MALAISE; MALARIA; MENTAL DISEASE; MICROSCOPY; MIGRAINE; MYALGIA; NAUSEA; NETHERLANDS; PARASITEMIA; PARESTHESIA; PHOTOSENSITIVITY; POLYMERASE CHAIN REACTION; PROTEINURIA; REPRODUCIBILITY; SIDE EFFECT; SORE THROAT; STIFF NECK; SYNCOPE; THORAX PAIN; THROMBOCYTE COUNT; TINNITUS; UNITED KINGDOM; UNITED STATES; VOMITING; ADULT; ANALYSIS OF VARIANCE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG EFFECT; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN EXPERIMENT; MALARIA FALCIPARUM; MALE; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PLASMODIUM FALCIPARUM; STANDARD; STATISTICS;

ADULT; ANALYSIS OF VARIANCE; CLINICAL TRIALS AS TOPIC; FEMALE; HUMAN EXPERIMENTATION; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PARASITEMIA; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC;

EID: 84862181254     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038434     Document Type: Article

References (37)

1. McCall MB, Netea MG, Hermsen CC, Jansen T, Jacobs L, et al. (2007) Plasmodium falciparum infection causes proinflammatory priming of human TLR responses. J Immunol 179: 162-171.
2. Sauerwein RW, Roestenberg M, Moorthy VS, (2011) Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 11: 57-64.
3. Andrews L, Andersen RF, Webster D, Dunachie S, Walther RM, et al. (2005) Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am J Trop Med Hyg 73: 191-198.
4. Felger I, Genton B, Smith T, Tanner M, Beck HP, (2003) Molecular monitoring in malaria vaccine trials. Trends Parasitol 19: 60-63.
5. Hermsen CC, Telgt DS, Linders EH, van de Locht LA, Eling WM, et al. (2001) Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol 118: 247-251.
6. Epstein JE, Rao S, Williams F, Freilich D, Luke T, et al. (2007) Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 196: 145-154.
7. Verhage DF, Telgt DS, Bousema JT, Hermsen CC, van Gemert GJ, et al. (2005) Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J Med 63: 52-58.
8. McCall MB, Beynon AJ, Mylanus EA, van d V, Sauerwein RW, (2006) No hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria. Trans R Soc Trop Med Hyg 100: 1098-1104.
9. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, et al. (2009) Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361: 468-477.
10. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, et al. (2011) Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet.
11. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, et al. (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24: 987-1003.
12. Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, et al. (2008) Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One 3: e1493.
13. Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, et al. (2006) A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 74: 5933-5942.
14. Walther M, Thompson FM, Dunachie S, Keating S, Todryk S, et al. (2006) Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun 74: 2706-2716.
15. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, et al. (2005) Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A 102: 4836-4841.
16. Walther M, Dunachie S, Keating S, Vuola JM, Berthoud T, et al. (2005) Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 23: 857-864.
17. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, et al. (2003) Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9: 729-735.
18. Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, et al. (2011) A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine 29: 7514-7522.
19. Bousema JT, Roeffen W, van der KM, de Vlas SJ, van d V, et al. (2006) Rapid onset of transmission-reducing antibodies in javanese migrants exposed to malaria in papua, indonesia. Am J Trop Med Hyg 74: 425-431.
20. Ponnudurai T, Lensen AH, van Gemert GJ, Bensink MP, Bolmer M, et al. (1989) Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Parasitology 98 Pt 2: 165-173.
21. Nieman AE, de MQ, Roestenberg M, Wiersma J, Pop G, et al. (2009) Cardiac complication after experimental human malaria infection: a case report. Malar J 8: 277-.
22. Visser HK, (2005) Experimental malaria in human volunteers: ethical aspects. Neth J Med 63: 41-42.
23. de Mast Q, Groot E, Lenting PJ, de Groot PG, McCall M, et al. (2007) Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria. J Infect Dis 196: 622-628.
24. de Mast Q, de Groot PG, van Heerde WL, Roestenberg M, van Velzen JF, et al. (2010) Thrombocytopenia in early malaria is associated with GP1b shedding in absence of systemic platelet activation and consumptive coagulopathy. Br J Haematol 151: 495-503.
25. Ali H, Ahsan T, Mahmood T, Bakht SF, Farooq MU, et al. (2008) Parasite density and the spectrum of clinical illness in falciparum malaria. J Coll Physicians Surg Pak 18: 362-368.
26. Beier JC, Davis JR, Vaughan JA, Noden BH, Beier MS, (1991) Quantitation of Plasmodium falciparum sporozoites transmitted in vitro by experimentally infected Anopheles gambiae and Anopheles stephensi. Am J Trop Med Hyg 44: 564-570.
27. Jin Y, Kebaier C, Vanderberg J, (2007) Direct microscopic quantification of dynamics of Plasmodium berghei sporozoite transmission from mosquitoes to mice. Infect Immun 75: 5532-5539.
28. Frischknecht F, Baldacci P, Martin B, Zimmer C, Thiberge S, et al. (2004) Imaging movement of malaria parasites during transmission by Anopheles mosquitoes. Cell Microbiol 6: 687-694.
29. Pumpuni CB, Mendis C, Beier JC, (1997) Plasmodium yoelii sporozoite infectivity varies as a function of sporozoite loads in Anopheles stephensi mosquitoes. J Parasitol 83: 652-655.
30. Ponnudurai T, Lensen AH, van Gemert GJ, Bolmer MG, Meuwissen JH, (1991) Feeding behaviour and sporozoite ejection by infected Anopheles stephensi. Trans R Soc Trop Med Hyg 85: 175-180.
31. Rickman LS, Jones TR, Long GW, Paparello S, Schneider I, et al. (1990) Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am J Trop Med Hyg 43: 441-445.
32. Jeffery GM, Young MD, Burgess RW, Eyles DE, (1959) Early activity in sporozoite-induced Plasmodium falciparum infections. Ann Trop Med Parasitol 53: 51-58.
33. Rosenberg R, Wirtz RA, Schneider I, Burge R, (1990) An estimation of the number of malaria sporozoites ejected by a feeding mosquito. Trans R Soc Trop Med Hyg 84: 209-212.
34. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, et al. (2010) Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6: 97-106.
35. Genton B, D'Acremont V, Lurati-Ruiz F, Verhage D, Audran R, et al. (2010) Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum. Vaccine 28: 6573-6580.
36. Trape JF, Zoulani A, (1987) Malaria and urbanization in central Africa: the example of Brazzaville. Part II: Results of entomological surveys and epidemiological analysis. Trans R Soc Trop Med Hyg 81: 10-18.
37. Moorthy VS, Diggs C, Ferro S, Good MF, Herrera S, et al. (2009) Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. Vaccine 27: 5719-5725.